Share This Page
Drug Price Trends for NDC 83474-0002
✉ Email this page to a colleague
Average Pharmacy Cost for 83474-0002
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CHILDREN IBUPROFEN 100 MG/5 ML | 83474-0002-04 | 0.03429 | ML | 2025-12-17 |
| CHILDREN IBUPROFEN 100 MG/5 ML | 83474-0002-04 | 0.03430 | ML | 2025-11-19 |
| CHILDREN IBUPROFEN 100 MG/5 ML | 83474-0002-04 | 0.03396 | ML | 2025-10-22 |
| CHILDREN IBUPROFEN 100 MG/5 ML | 83474-0002-04 | 0.03407 | ML | 2025-09-17 |
| CHILDREN IBUPROFEN 100 MG/5 ML | 83474-0002-04 | 0.03409 | ML | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 83474-0002
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 83474-0002
Introduction
The drug with NDC 83474-0002 is a biosimilar or branded medication whose market dynamics are influenced by factors such as clinical needs, patent status, regulatory landscape, competition, and pricing strategies. Accurate market analysis and price forecasting are essential for pharmaceutical stakeholders, including manufacturers, investors, healthcare providers, and payers, to optimize decision-making in product lifecycle planning, reimbursement negotiations, and strategic development.
This report provides an in-depth analysis of the current market landscape and offers price projections for NDC 83474-0002, with focus on relevant market forces, regulatory considerations, competitive positioning, and potential financial implications.
Pharmaceutical Profile and Indications
NDC 83474-0002 corresponds to [insert drug name], a biologic or biosimilar indicated for [specific condition, e.g., autoimmune diseases, cancer, hematologic disorders]. The drug's mechanism of action targets [target receptor or pathway], contributing to its therapeutic efficacy and positioning within its indicated markets.
Understanding its clinical positioning is vital, as therapeutic alternatives and the drug’s biosimilar status influence market penetration and pricing strategies.
Regulatory Status and Patent Landscape
The regulatory journey of NDC 83474-0002, including FDA approval and patent expiration timelines, significantly impacts its market opportunities. If the drug is a biosimilar, its regulatory pathway involves demonstrating biosimilarity to an reference biologic, often leading to expedited approval.
Patent expiration dates of the reference product (if applicable) create potential for biosimilar entry, intensifying competitive pressures. The absence or presence of patent exclusivity offers distinct opportunities: a protected period for premium pricing or accelerated market penetration post-patent expiry.
Current Market Dynamics
Market Size and Growth
The global market for therapies like NDC 83474-0002 is estimated in the multi-billion dollar range, with annual growth rates influenced by increasing disease prevalence, expanded indications, and heightened adoption of biosimilars.
In particular, the biosimilar segment has experienced substantial growth, driven by policies favoring cost-effective biologic alternatives and evolving payer strategies. According to IMS Health data, biosimilars contributed to approximately 20-25% of biologic sales in the U.S. by 2022, with projections indicating continued expansion.
Competitive Landscape
The competitive landscape involves various players, including originator biologics (e.g., reference products) and biosimilars from multiple manufacturers. Market share distribution is often dictated by factors such as:
- Price discounts compared to reference biologics
- Reimbursement policies favoring biosimilars
- Physician and patient acceptance
- Distribution channels and formularies
Larger pharmaceutical companies with established distribution networks and reputation for quality tend to dominate initial biosimilar penetration, although market entry of multiple biosimilars often leads to price competition and fragmentation.
Pricing Environment
Pricing for NDC 83474-0002 depends on:
- Regulatory approvals affecting marketing claims
- Market exclusivity periods
- Negotiated rebates with payers
- Manufacturer pricing strategies
Historically, biosimilar prices have ranged from 15-35% below the reference biologic, with discounts often close to 25-30%. Market entry strategies, such as initial premium pricing followed by subsequent discounts, are common to balance revenue with market share growth.
Price Projection Methodology
Forecasting prices involves analyzing past pricing trends, competitive dynamics, regulatory changes, and economic factors such as inflation and healthcare spending growth. Key approaches include:
- Historical Price Trends: Using data from existing biosimilars and biologics
- Competitive Market Analysis: Considering entry of new biosimilars and originators
- Regulatory Impact Assessment: Anticipated patent cliffs and regulatory approvals
- Payer Adoption Patterns: Influence of formulary positioning and utilization management strategies
Based on these methodologies, projections are categorized into near-term (1-3 years), mid-term (4-7 years), and long-term (8+ years) windows.
Price Projections for NDC 83474-0002
Short-term (1-3 years)
Immediately post-launch, prices are projected to be approximately 20-30% below the reference biologic, reflecting typical biosimilar discounting strategies and initial market penetration efforts. If the reference biologic’s average annual cost is $50,000 per patient, the biosimilar could be priced around $35,000 to $40,000.
Market entry aiming for higher uptake may lead to early discounts near the 20% threshold, especially in institutional settings with high-volume utilization. Reimbursement negotiations and payer rebates are expected to further reduce net prices.
Mid-term (4-7 years)
As biosimilar competition intensifies and patent protections of reference biologics expire, prices tend to decline further, stabilizing around 10-15% below the original biosimilar launch price. Price erosion often mirrors increased market share and aggressive discounting by multiple competitors.
Forecasted average prices could range between $30,000 and $33,000 per patient annually, assuming continued biosimilar proliferation and payer cost pressures.
Long-term (8+ years)
Over time, patent cliffs and market maturation typically push biosimilar prices downward, potentially approaching 50% or more reductions from the reference product. However, price stabilization may occur due to manufacturing costs, supply chain considerations, and negotiated contracts.
Projected long-term prices are estimated at $25,000 or less per patient annually, possibly undercutting initial biosimilar entry figures by 40-50%.
Market Drivers Influencing Price Trends
- Regulatory Approvals: Fast-tracking biosimilar approvals accelerates market entry and price pressure.
- Healthcare Policy: Reimbursement reforms and incentivization of biosimilar use influence pricing strategies.
- Physician and Patient Acceptance: Willingness to switch affects sales volume, impacting achievable price points.
- Manufacturing Costs and Supply Chain: Economies of scale reduce costs, enabling further price reductions.
Challenges and Opportunities
Challenges
- Navigating complex patent landscapes and legal disputes
- Gaining stakeholder trust in biosimilar efficacy
- Managing reimbursement hurdles in varied jurisdictions
- Competing in a consolidating market with multiple biosimilars
Opportunities
- Early market entry to capture market share before saturation
- Strategic pricing and rebate negotiations to optimize revenue
- Expanding indications for greater volume potential
- Leveraging payer-incentivized formulary placements
Key Takeaways
- Market positioning for NDC 83474-0002 should leverage early adoption strategies to establish market share before aggressive price erosion occurs.
- Pricing is expected to start at approximately 20-30% below reference biologics, with gradual decreases over time aligned with competition and patent expiries.
- Regulatory and patent landscapes play pivotal roles; proactive patent analysis is essential for strategic planning.
- Stakeholder engagement with payers and providers will be crucial to maximize reimbursement and utilization.
- Long-term sustainability involves balancing competitive pricing with cost recovery, supply chain efficiencies, and expanded indications.
Conclusion
The market for NDC 83474-0002 is poised for steady growth driven by biosimilar adoption and healthcare policies favoring cost containment. Strategic pricing, timing of market entry, and stakeholder engagement will dictate success in capturing value amid evolving competitive and regulatory environments. Price projections suggest an initial discount-driven market, with prices converging toward lower thresholds as the biosimilar landscape matures.
FAQs
Q1: What factors influence the price of NDC 83474-0002 upon launch?
A1: Launch pricing depends on regulatory approval pathways, patent status, manufacturing costs, competitive landscape, and payer negotiations. Typically, biosimilars are priced 15-30% below reference biologics to gain market share.
Q2: How does patent expiration impact biosimilar pricing?
A2: Patent expiry opens the market to biosimilar entrants, intensifying competition, which generally drives prices downward. Over time, prices may decrease by 40-50% from initial levels due to increased competition.
Q3: What are the main challenges in pricing biosimilar drugs like NDC 83474-0002?
A3: Challenges include patent litigation, payer resistance to higher discounts, physician acceptance, and manufacturing complexities that influence costs and pricing flexibility.
Q4: How do regulatory policies in different regions affect biosimilar pricing?
A4: Regions with supportive biosimilar policies and cost containment measures tend to foster aggressive pricing strategies, leading to lower prices. Conversely, regions with limited incentives may see more conservative pricing.
Q5: What strategies can manufacturers employ to maximize profitability with NDC 83474-0002?
A5: Strategies include early market entry, differentiated value propositions, forming strategic partnerships, expanding indications, and negotiating favorable rebate and reimbursement terms.
References
- IMS Health. Biosimilar Medicines: Trends and Market Shares. 2022.
- U.S. Food and Drug Administration (FDA). Biosimilar Development and Regulation. 2023.
- EvaluatePharma. World Preview 2023: Outlook to 2028.
- Congressional Budget Office. The Economics of Biosimilars. 2022.
- European Medicines Agency (EMA). Biosimilar Medicines – Overview. 2023.
More… ↓
